SCILEX Pharmaceuticals Announces Appointments of Internationally Recognized Industry Experts
- Dr. Sanjay Gupta, President of the American Pain Association and a renowned physician with pain management expertise
- Dr. Philip Gerbino, an award-winning global pharmaceutical consultant and industry expert on market access
MALVERN, Pa., June 8, 2015 /PRNewswire/ — SCILEX Pharmaceuticals, Inc., a company engaged in the development and commercialization of products focused on the treatment of pain, today announced two appointments: Dr. Sanjay Gupta, a renowned physician with pain management expertise, to its Scientific Advisory Board; and Dr. Philip Gerbino, an award-winning global pharmaceutical consultant, as a Strategic Advisor.
These appointments further strengthen SCILEX’s proprietary drug development program, which includes ZTlido™ (lidocaine patch 1.8%) a next-generation patch being developed for the treatment of postherpetic neuralgia, or after-shingles pain.
“These executives bring a wealth of expertise in pain management, global pharmaceutical consulting and distinguished academic credentials. This will enable us to further sharpen our competitive edge as we explore additional products for the treatment of pain,” said Anthony Mack, Chief Executive Officer of SCILEX.
Dr. Gupta has more than 20 years of experience in pain management and is the director of Atlantic Pain Institute. His experience includes President of the American Pain Association, membership of the Pain News editorial board and executive producer for HealthTime TV. His research work covers the spectrum of pain management and Dr. Gupta has received several academic honors and awards, including the Henry Ford Health Research Award and Michiganian of the Year Award. He completed a pain fellowship at Harvard University and was chief resident at the Henry Ford Hospital in Detroit.
Dr. Gupta joins other internationally renowned physicians on SCILEX’s Scientific Advisory Board, whose focus it is to provide advice to identify and advance product candidates for the Company’s portfolio. In addition to its newly appointed members, the Scientific Advisory Board consists of: Jeffrey Gudin, MD; Charles Argoff, MD; Srinivas Nalamachu, MD and Regulatory and Strategic Development Consultant, Kip Vought.
Dr. Gerbino has been recognized with leadership awards from pharmaceuticals giants such as Merck and Proctor and Gamble, reflecting a career which has seen him counsel significant industry players on market access in Asia, Europe and the U.S. He is currently President Emeritus at the Philadelphia College of Pharmacy and has been Chairman-Elect of the American Pharmaceutical Association among a host of other senior industry and academic board positions. Dr. Gerbino has consulted to companies such as Novartis, GlaxoSmithKline and Bristol-Myers Squibb. He received his Bachelor of Science and Doctor of Pharmacy from the Philadelphia College of Pharmacy and Science.
About SCILEX Pharmaceuticals
SCILEX Pharmaceuticals, Inc., located in Malvern, PA, is an emerging specialty pharmaceutical company engaged in the development and commercialization of late-stage pharmaceutical products focused on the treatment of pain. The Company’s vision is to become a world-class, global pharmaceutical company that delivers the next generation of innovative products. Leveraging its network of global relationships, the Company seeks to acquire high barrier-to-entry, late-stage products for development and commercialization. The Company’s first product under development, ZTlido™ (lidocaine patch 1.8%), is a next-generation branded lidocaine patch formulation for the potential treatment of relieving the pain of postherpetic neuralgia, also referred to as after-shingles pain. For more information visit www.scilexpharma.com
ZTlido™ is a trademark owned by SCILEX Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners. A proprietary name review by the FDA is planned. © 2015 SCILEX Pharmaceuticals, Inc. All Rights Reserved.